Chronic Lower Back Pain (CLBP) - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight’s "Chronic Lower Back Pain (CLBP)—Market Insights, Epidemiology, and Market Forecast–2032" report deliver an in-depth understanding of the CLBP, historical and forecasted epidemiology as well as the CLBP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The CLBP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CLBP market size from 2019 to 2032. The Report also covers current CLBP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032
Chronic Lower Back Pain (CLBP) Disease Understanding and Treatment Algorithm
CLBP Overview
Chronic low back pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is widespread and likely to affect everyone at one point. The exact cause of lower back pain is not found yet. Lower back pain that is long-term (for more than 3 months) is called CLBP. This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe. CLBP is the second leading cause of disability worldwide, being a major welfare and economic problem. The prevalence of CLBP in adults has increased significantly in the last decade and is continuously increasing vividly in the aging population. This condition affects men and women in all ethnic groups equally. This disease also leads to stress, depression, and anxiety. CLBP has adverse physical and psychological repercussions. It creates a significant economic burden due to loss of function, loss of work productivity, treatment costs, and disability payments.
CLBP originates from different conditions and may start from diseases, injuries, or stress to many different anatomic structures, including bones, muscles, ligaments, joints, nerves, or the spinal cord. The affected structure sends a signal through nerve endings, up to the spinal cord and into the brain, where it registers as pain.
Several theories have been given to explain or find out the exact underlying cause of CLBP, but it is believed that the nerve pathways that carry the pain signals from the nerve endings through the spinal cord and to the brain may become sensitized. Sensitization of these pathways may increase the frequency or intensity of the signals with which pain is perceived. Sometimes when the condition has been treated, the sensitized pathway continues to send signals to the brain, which sometimes, with great intensity, causes immense pain and feels just as real as the pain caused by the original injury or disease.
Continued in the report…..
CLBP Diagnosis
CLBP is usually investigated by physician evaluation or by imaging studies. The primary goal of diagnosis is to characterize the pain as mechanical, primarily when history is obtained from a patient with CLBP and sciatica. Mechanical or activity-related spinal pain is most often aggravated by static loading of the spine (prolonged sitting or standing), long-lever activities (vacuuming or working with the arms elevated and away from the body), and levered postures (forward bending of the lumbar spine). Pain is reduced when multidirectional forces balance the spine (walking or constantly changing positions) and when the spine is unloaded. Patients with mechanical LBP often prefer to lie still in bed. In contrast, those with a vascular or visceral cause are often found writhing in pain, unable to find a comfortable position.
Continued in the report…..
CLBP Treatment
CLBP is the most prevalent chronic pain condition and the second most common cause of disability in the US, after arthritis or rheumatism. CLBP may be nociceptive or neuropathic or include both components. The presence of a neuropathic component is related to the more intense pain of longer duration and a higher prevalence of comorbidities. The actual mechanism and cause of CLBP are still unknown, and due to this situation, there are no universally accepted treatment guidelines, and the management of the treatment is limited. If the source of the pain is not known or cannot be treated, the best option remains is to reduce the flare-ups and to make the pain manageable with nonsurgical treatments. There are nonsurgical treatments (physical therapy, diet, meditation, and lifestyle modifications), injection-based treatments, and pharmacologic treatments.
Continued in the report…..
CLBP Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent population of CLBP, total diagnosed prevalent population of CLBP, gender-specific diagnosed prevalence of CLBP, and age-specific diagnosed prevalence of CLBP scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Key Findings
• In 2020, the total prevalent population of chronic lower back pain were found out to be 76,440,725 in the 7MM, these cases are expected to grow at a CAGR of 0.55% for the study period 2019–2020.
• The estimates suggest the highest diagnosed prevalent cases of CLBP in the United States with 35,059,702 cases in 2020.
• The total number of CLBP cases in females was the 17,291,445 and in males it was 14,262,287 cases in 2020, in the US.
• The highest number of CLBP cases were in the age group 70+ years with 6,736,354 cases in the EU-5 and the least number of cases of CLBP were found in 18–29 years age group with 2,363,980 cases in 2020, in EU-5.
• Japan had 10,826,931 diagnosed prevalent cases of CLBP in 2020.
CLBP Epidemiology
The epidemiology segment also provides the CLBP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
CLBP Drug Chapters
CLBP Emerging Drugs
Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
Brixadi (CAM2038/buprenorphine injection depot) is a novel, ready-to-use, long-acting, investigational buprenorphine weekly and monthly subcutaneous depot injection for flexible and individualized treatment of both moderate-to-severe opioid use disorder and moderate-to-severe chronic pain. The drug is a partial agonist at the mu-opioid receptor and exhibits antagonistic effects at the kappa opioid receptor.
Semdexa (SP-102): Scilex Holding
Semdexa (SP-102, dexamethasone sodium phosphate) is a nonopioid corticosteroid formulated as a viscous gel injection that is under development to treat lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents, or particulates. Because of these properties, the drug is expected to result in a better safety profile than commonly used off-label injected corticosteroids. SP-102 has an ingredient that is a widely used corticosteroid solution. Corticosteroids have been given epidurally (directly into the spine) for the pain caused by sciatica since about 1970; however, there is no US FDA–approved injectable corticosteroid for sciatica. SP-102 is a treatment intended to produce an anti‑inflammatory effect from the widely used corticosteroid solution, and it is intended to last longer than other steroid injections possibly used by your doctor to treat sciatica.
Products detail in the report…
List to be continued in the report…
CLBP Market Outlook
CLBP is a complex process and comparable to how each patient has a very individualized disease process the treatment regimen is similarly individualized. There are several different medication classes, each with an exclusive mechanism of action that can help the practitioner in targeting a specific aspect of a patient's pain. Moreover, patient‐specific factors are taken into account when developing a regimen to ensure adherence and improve outcomes.
Prior to initiating any pharmacologic treatment regimen for a patient, current consensus recommendations include discussing realistic expectations with the patient. This includes the expectation of a patient in terms of pain relief as well as functional goals that the patient should work toward. Additionally, clinicians encourage self‐care and education with evidence‐based materials.
Continued in the report…..
Key Findings
• The market size of CLBP in the 7MM is expected to rise from USD 6,227 million in 2020 at a CAGR of 3.85% for the study period (2019–2032).
• The United States accounted for the highest market size of CLBP, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan in 2020.
• Among the EU5 countries, Spain had the highest market size with USD 317 million in 2020, while Italy had the lowest market size of CLBP with USD 94 million in 2020.

The United States Market Outlook
This section provides the total CLBP market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total CLBP market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total CLBP market size and market size by therapies in Japan are provided.
CLBP Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the CLBP market or expected to get launched in the market during the study period 2019–2032. The analysis covers the CLBP market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
CLBP Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for CLBP emerging therapies.
Reimbursement Scenario in chronic lower back pain
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the CLBP market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
• The report covers the descriptive overview of CLBP, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the CLBP epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for CLBP is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the CLBP market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM CLBP market.
Report Highlights
• The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the CLBP market.
• The companies and academics are working to assess challenges and seek opportunities that could influence chronic lower back pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for CLBP. The launch of emerging therapies will significantly impact the CLBP market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
CLBP Report Insights
• Patient Population
• Therapeutic Approaches
• CLBP Pipeline Analysis
• CLBP Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
CLBP Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• CLBP Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

CLBP Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis
Key Questions
Market Insights:
• What was the CLBP market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the CLBP total market size as well as market size by therapies across the 7MM during the forecast period (2021–2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest CLBP market size during the forecast period (2021–2032)?
• At what CAGR, the CLBP market is expected to grow at the 7MM level during the forecast period (2021–2032)?
• What would be the CLBP market outlook across the 7MM during the forecast period (2021–2032)?
• What would be the CLBP market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• Epidemiology Insights:
• What are the disease risk, burdens, and unmet needs of CLBP?
• What is the historical CLBP patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of CLBP at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CLBP?
• Out of the above-mentioned countries, which country would have the highest incident population of CLBP during the forecast period (2021–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of CLBP along with the approved therapy?
• What are the current treatment guidelines for the treatment of CLBP in the US and Europe?
• What are the CLBP marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of CLBP?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of CLBP?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CLBP therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CLBP and their status?
• What are the key designations that have been granted for the emerging therapies for CLBP?
• What are the 7MM historical and forecasted market of CLBP?
Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving CLBP.
• To understand the future market competition in the CLBP market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for CLBP in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the CLBP market.
• To understand the future market competition in the CLBP market.